These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 37011983)

  • 1. [Analysis of 7 cases of pediatric acute myeloid leukemia with DEK-NUP214 fusion gene].
    Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
    Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1.
    Liu L; Nie Q; Xiao Z; Chen X; Yang C; Mao X; Li N; Zhou Y; Guo Q; Tian X
    BMC Pediatr; 2024 Jul; 24(1):483. PubMed ID: 39068406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
    Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic significance of DEK-NUP214 fusion gene in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Gao MG; Fu Q; Qin YZ; Chang YJ; Wang Y; Yan CH; Xu LP; Zhang XH; Huang XJ; Zhao XS
    Zhonghua Nei Ke Za Zhi; 2021 Oct; 60(10):868-874. PubMed ID: 34551474
    [No Abstract]   [Full Text] [Related]  

  • 7. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
    Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
    Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
    Zhang X; Zhang X
    Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of therapeutic effects of allogeneic hematopoietic stem cell transplantation in 12 patients with DEK-NUP214 fusion gene positive acute myeloid leukemia].
    Shen YY; Yang DL; He Y; Pang AM; Chen X; Ma QL; Zhang RL; Wei JL; Zhai WH; Han MZ; Jiang EL; Feng SZ
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):383-387. PubMed ID: 38951067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
    Wang F; Xie M; Chen P; Wang D; Yang M
    Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the efficacy of IA and HAD induction regimens in the treatment of patients with newly diagnosed acute myeloid leukemia: a single-center study].
    Zhang CX; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Wei SN; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):383-387. PubMed ID: 35680595
    [No Abstract]   [Full Text] [Related]  

  • 12. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.
    Sandahl JD; Coenen EA; Forestier E; Harbott J; Johansson B; Kerndrup G; Adachi S; Auvrignon A; Beverloo HB; Cayuela JM; Chilton L; Fornerod M; de Haas V; Harrison CJ; Inaba H; Kaspers GJ; Liang DC; Locatelli F; Masetti R; Perot C; Raimondi SC; Reinhardt K; Tomizawa D; von Neuhoff N; Zecca M; Zwaan CM; van den Heuvel-Eibrink MM; Hasle H
    Haematologica; 2014 May; 99(5):865-72. PubMed ID: 24441146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcomes of adult patients with
    Ren X; Zhao T; Wang J; Zhu HH; Jiang H; Jia JS; Yang SM; Jiang B; Wang DB; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):15-21. PubMed ID: 29551027
    [No Abstract]   [Full Text] [Related]  

  • 15. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
    Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
    Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of venetoclax-based induction regimen in newly diagnosed pediatric acute myeloid leukemia].
    Wen XJ; Lu Y; Huang PL; Zhang YY; Yu JJ; Qi PJ; Huang Q; Yang J; Liu HQ; Hou B; Wang LY; Li HQ; Lin W; Wu Y; Zhang RD; Li J; Luo D; Li YN; Liu M; Zhao ZW; Liu Y; Zheng HY
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(27):2513-2520. PubMed ID: 38978375
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
    Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
    Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.